Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ibrance
Pharma
Roche burnishes breast cancer portfolio with FDA nod for Itovebi
To be marketed under the brand name Itovebi, inavolisib is a threat to Novartis’ fellow PI3K inhibitor Piqray and AstraZeneca’s AKT inhibitor Truqap.
Angus Liu
Oct 10, 2024 5:30pm
Pfizer sees 8 blockbuster cancer drugs from each focus area
Jun 13, 2024 12:45pm
AbbVie's Humira, J&J's Darzalex top ICER's annual price-hike list
Dec 11, 2023 11:26am
Lilly's Verzenio barely misses overall survival goal in 1L
Dec 6, 2023 10:00am
Bristol Myers dominates list of the most seen ASCO display ads
Jun 28, 2023 4:56am
Intra-Cellular winner of the Fierce Madness Drug Ad Tournament
Mar 22, 2023 8:30am
